Bone Metastases: Assessment of Therapeutic Response through Radiological and Nuclear Medicine Imaging Modalities

Clinical Oncology

Volumn 23, Issue 9, 2011, Pages 632-645

  Vassiliou, V ^a   Andreopoulos, D ^a   Frangos, S ^a   Tselis, N ^b   Giannopoulou, E ^c   Lutz, S ^d  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b Klinikum Offenbach   (Germany)

^c UNIVERSITY OF PATRAS   (Greece)

^d Blanchard Valley Regional Cancer Center   (United States)

Author keywords

Bisphosphonates; Bone metastases; Chemotherapy; Imaging; Radiotherapy; Therapeutic response

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; METHIONINE C 11; ZOLEDRONIC ACID;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG MONITORING; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION RESPONSE; RADIODIAGNOSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ABSORPTIOMETRY, PHOTON; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053385977     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.03.010     Document Type: Article

References (95)

1. Brown H.K., Healy J.H. Cancer - principles and practice of oncology 2001, 2713-2719. Lippincott Williams and Wilkins, Philadelphia. 6th ed. V.T. De Vita, S. Hellman, S.A. Rosenberg (Eds.).
2. Vassiliou V., Kalogeropoulou C., Christopoulos C., et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 2007, 67:264-272.
3. Vassiliou V., Kalogeropoulou C., Giannopoulou E., et al. A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 2007, 24:169-178.
4. Saad F., Lipton A., Cook R., et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
5. Coleman R., Rubens R. The clinical course of bone metastases in breast cancer. Br J Cancer 1987, 55:61-66.
6. Hoskin P.J. Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv 1988, 7:69-86.
7. Chow E., Harris K., Fan G., et al. Palliative radiotherapy trials for bone metastases. A systematic review. J Clin Oncol 2007, 25:1423-1436.
8. Sze W.M., Shelley M.D., Held I., et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. A systematic review of randomized trials. J Clin Oncol 2003, 15:345-352.
9. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 2004, 9:14-27.
10. Krempien R., Niethammer A., Harms W., Debus J. Bisphosphonates and bone metastases: current status and future directions. Expert Rev Anticancer Ther 2005, 5:295-305.
11. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
12. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003, 14:1399-1405.
13. Pavlakis N., Stocker M. Bisphosphonates for breast cancer. Cochrane Library 2002, (Issue. 1).
14. Body J.J., Diel I.J., Lichinitser M., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer 2004, 90:1133-1137.
15. Hortobagyi G.N., Theriault R., Lipton A., et al. Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998, 16:2038-2044.
16. Khono N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
17. Rosen L., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 15(21):3150-3157.
18. Brown J.E., Neville-Webbe H., Coleman R.E. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004, 11:207-224.
19. Body J.J., Diel I.J., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004, 111:306-312.
20. Gralow J., Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage 2007, 33:462-472.
21. Diel I.J., Body J.J., Lichinitser M.R., et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004, 40:1704-1712.
22. Diel I.J. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 2007, 15:1243-1249.
23. Lewington V.J. Bone-seeking radionuclides for therapy. J Nucl Med 2005, 46:38s-47s.
24. Finlay I.G., Mason M.D., Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005, 6:392-400.
25. Vassiliou V., Kardamakis D. The management of metastatic bone disease with the combination of bisphosphonates and radiotherapy: from theory to clinical practice. Anticancer Agents Med Chem 2009, 9:326-335.
26. Vassiliou V., Bruland O., Janjan N., et al. Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness. Clin Oncol 2009, 21:665-667.
27. Fizazi K., Beuzeboc P., Lumbroso J., et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009, 27:2429-2435.
28. Morris M.J., Pandit-Taskar N., Carrasquillo J., et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 2009, 27:2436-2442.
29. Lam M.G., Dahmane A., Stevens W.H., et al. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2008, 35:756-765.
30. Storto G., Klain M., Paone G., et al. Combined therapy Sr-89 and Zoledronic acid in patients with painful bone metastases. Bone 2006, 39:35-41.
31. Heyward J.L., Carbone P.P., Heusen J.C., et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977, 35:292-298.
32. World Health Organization (WHO) Handbook for reporting results of cancer treatment 1979, World Health Organiztion, Geneva.
33. Hamaoka T., Madewell J.E., Podolff D.A., et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004, 22:2942-2953.
34. Hamaoka T., Castelloe C.M., Madewell J.E., et al. Tumor response interpretation with new response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 2010, 102:651-657.
35. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
36. Chow E., Jackson S.Y., Hoskin P., et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 2002, 64:275-280.
37. Lutz S., Hoskin P., Chow E. Update on palliative radiotherapy endpoints for bone metastasis trials. Clin Oncol 2009, 21:659-661.
38. Galasko C.S.D. Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop Relat Res 1995, 312:64-75.
39. Vassiliou V., Kardamakis D. Types of bone metastases in women with breast cancer undergoing systemic treatments. Radiol Med 2008, 113:771-773.
40. Body J.J. Metastatic bone disease: clinical and therapeutic aspects. Bone 1992, 13:557-562.
41. Clamp A., Danson S., Nguyen H., et al. Assessment of therapeutic response in patients with metastastic bone disease. Lancet Oncol 2004, 5:607-616.
42. Southard T.E., Southard K.A. Detection of simulated osteoporosis in maxillae using radiographic texture analysis. IEEE Trans Biom Eng 1996, 43:123-132.
43. Heller M., Majewski H., Crone-Münzebrock W., et al. Roentgen morphology of bone metastases of breast cancer as affected by antineoplastic therapy. Rofo 1988, 149:121-128.
44. Huber S., Ulsperger E., Gomar C., et al. Osseous metastases in breast cancer: radiographic monitoring of therapeutic response. Anticancer Res 2002, 22:1279-1288.
45. Kouloulias V.E., Kouvaris R.J., Antypas C., et al. An intrapatient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Strahlenther Onkol 2003, 179:471-479.
46. Kouloulias V.E., Dardoufas C.E., Kouvaris J.R., et al. Use of image processing techniques to assess effect of disodium pamidronate in conjunction with radiotherapy in patients with bone metastases. Acta Oncol 2002, 41:169-174.
47. Kouloulias V., Matsopoulos G., Kouvaris J., et al. Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys 2003, 57:143-157.
48. Kouloulias V., Antypas C., Dardoufas C., et al. Evaluation of recalcification of bone metastases after radiotherapy and i.v. infusion of disodium pamidronate, using image processing techniques. Comparative assessment using measurements of the optical density of plain radiography. Phys Med 2001, XVII:17-24.
49. Galasko C.S.B. The pathophysiological basis for skeletal scintigraphy. Radionuclide scintigraphy in orthopedics 1984, 34-39. Churchill Livingstone, Edinburgh. C.S.B. Galasko, D.A. Weber (Eds.).
50. Scher H. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer Suppl 2003, 97:758-771.
51. Cook G.J., Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med 2001, 31:206-211.
52. Vogel C.L., Schoenfelder J., Shemano I., et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995, 13:1123-1128.
53. Rossleigh M.A., Lovergrove F.T., Reynolds P.M., et al. The assessment of response to therapy of bone metastases in breast cancer. Aust N Z J Med 1984, 14:19-22.
54. Janicek M., Hayes D., Kaplan W. Healing flare in skeletal metastases from breast cancer. Radiology 1994, 192:201-204.
55. Lokich J.J. Osseus metastases: radiographic monitoring of therapeutic response. Oncology 1978, 35:274-276.
56. Citrin D.L., Hougen C., Zweibel W., et al. The use of serial bone scans in assessing response of bone metastases to systemic treatment. Cancer 1981, 47:680-685.
57. Chavdarova L., Piperkova L., Tsonevska A., et al. Bone scintigraphy in the monitoring of treatment effect of bisphosphonates in bone metastatic breast cancer. J BUON 2006, 11:499-504.
58. Hortobagyi G.N., Libshitz H.I., Seabold J.E. Osseous metastases of breast cancer. Clinical, biochemical, radiographic and scintigraphic evaluation of response to therapy. Cancer 1984, 53:577-582.
59. Sabbatini P., Larson S.M., Kremer A., et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999, 17:948-957.
60. Yohara J., Noguchi M., Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU 2003, 92:379-383.
61. Berruti A., Dogliotti L., Osella G., et al. Evaluation by dual energy x-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. Oncol Rep 2000, 7:777-781.
62. Smith G.L., Doherty A.P., Banks L.M., et al. Dual x-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients. Clin Exp Metastasis 2001, 18:385-390.
63. Shapiro C.L., Keating J., Angell J.E., et al. Monitoring therapeutic response in skeletal metastases using dual-energy X-ray absorptiometry: a prospective feasibility study in breast cancer patients. Cancer Invest 1999, 17:566-574.
64. Inoka T., Takehashi K., Aburano T., et al. Spinal metastasis from lung cancer fifteen years after surgery presenting a pseudohemangioma appearance of the vertebra: a case report. Spine 2010, 35:86-89.
65. Rafii M., Firooznia H., Golimbu C., Beranbaum E. CT of skeletal metastasis. Semin Ultrasound CT MR 1986, 7:371-379.
66. Reinbold W.D., Wannenmachen M., Hodapp N., Adler C.P. Osteodensitometry of vertebral metastases after radiotherapy using quantitative computed tomography. Skeletal Radiol 1989, 18:517-521.
67. Chow E., Holden L., Rubenstein J., et al. Computed tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy - a feasibility study. Radiother Oncol 2002, 64:275-280.
68. Koswig S., Budach V. Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs 1 time 8 Gy). A prospective study. Strahlenther Onkol 1999, 175:500-508.
69. Wachenfeld I., Sanner G., Böttcher H.D., Kollath J. The remineralisation of the vertebral metastases of breast carcinoma after radiotherapy. Strahlenther Onkol 1996, 172:332-341.
70. Grone-Münzebrock W., Spielmann R.P., Brockmann W.P. Clinical studies of the quantitative changes in mineral salt content of irradiated vertebral body metastases with 2-energy computerized tomography. Rontgenblatter 1988, 41:223-228.
71. Vassiliou V., Kalogeropoulou C., Leotsinidis M., et al. Management of symptomatic bone metastases from breast cancer with concomitant use of external radiotherapy and ibandronate: results of a prospective, pilot study. Breast J 2010, 16:92-94.
72. Vassiliou V., Leotsinides M., Kalogeropoulou C., Kardamakis D. Concurrent application of bisphosphonates and external beam radiotherapy in patients with metastatic bone disease from renal cancer. Br J Urol Int 2009, 104:417-418.
73. Grant V.B., Owers R., Evans A.J., Cheung K.L. Should computerized tomography (CT) replace abdominal ultrasonography and chest radiographs (USG +CXR) as initial staging investigation for visceral disease in patients with metastatic breast cancer (MBC)?. Eur J Cancer 2005, (Suppl. 3):S33.
74. Bristow A.R., Agrawal A., Evans A.J., et al. Can computerized tomography replace bone scintigraphy in detecting bone metastases from breast cancer? A prospective study. Breast 2008, 17:98-103.
75. Whitlock J.P.L., Evans A.J., Jackson L., et al. Imaging of metastatic breast cancer: distribution and radiological assessment at presentation. Clin Oncol 2001, 13:181-186.
76. Ghanem N., Altehoefer C., Högerle S., et al. Comparative diagnostic value and therapeutic relevance of magnetic resonance imaging and bone marrow scintigraphy in patients with metastatic solid tumours of the axial skeleton. Eur J Radiol 2002, 43:256-261.
77. Ciray I., Lindman H., Astrom K.G., et al. Early response of breast cancer bone metastases to chemotherapy evaluated by MR imaging. Acta Radiol 2001, 42:198-206.
78. Brown A.L., Middleton G., MacVicar A.D., Husband E.S. T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol 1998, 53:935.
79. Saip P., Tenekeci N., Aydiner A., et al. Response evaluation of bone metastases in breast cancer: value of magnetic resonance imaging. Cancer Invest 1999, 17:575-580.
80. Tombal B., Rezazadeh A., Therasse P., Cangh P.J.V. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005, 65:178-187.
81. Montemuro F., Russo F., Martiacich L., et al. Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta Radiol 2004, 45:71-74.
82. Freedman O., Clemons M., Vassiliou V., et al. Cancer metastasis - biology and treatment 12: bone metastases: a translational and clinical approach: assessment of therapeutic response 2009, Springer, Berlin, pp. 345-370.
83. Byun W.M.B., Shin S.O., Chang Y., et al. Diffusion-weighted MR images of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol 2002, 23:906-912.
84. Cook G., Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000, 88:2927-2933.
85. Ohta M., Tokuda Y., Suzuki Y., et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDp bone scintigraphy. Nucl Med Commun 2001, 22:875-879.
86. Wu H., Yen R., Shen Y.Y., et al. Comparing whole body 18f-2-deoxyglucose positron emission tomography and technetium 99 methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas: a preliminary report. J Cancer Res Clin Oncol 2002, 128:503-506.
87. Cook G.J., Houston S., Rubens R., et al. Detection of bone metastases in breast cancer by 18 FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998, 26:3375-3379.
88. Shreve P., Grossman H., Gross M., Wahl R.L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology 1996, 199:751-756.
89. Stafford S.E., Gralow J.R., Schubert E.K., et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002, 9:913-921.
90. Gwak H.S., Youn S.M., Chang U., et al. Usefulness of (18)F-fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis. Minim Invasive Neurosurg 2006, 49:127-134.
91. Lindholm P., Lapela M., Nagren K. Preliminary study of carbon -11-methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun 2009, 30:30-36.
92. Tateishi U., Gamez C., Dawood S., et al. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PETCT. Radiology 2008, 247:189-196.
93. Du Y., Cullum I., Illidge T.M., Ell P.J. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007, 25:3440-3447.
94. Dehtashti F., Flanagan F.L., Mortimer J.E., et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999, 26:51-56.
95. Vassiliou V., Andreopoulos D. Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria. Br J Cancer 2010, 103:925-926.